A Phase 3 interventional study of HOE901-U300 (Insulin glargine new formulation) and Lantus (Insulin glargine) in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 147 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-24.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is one of 8 that started in 2012, is one of 18 in phase 3, and was the 39th registered.
3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 549 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 73 across the 66 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 66 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
67 studies in Diabetes Mellitus, Type 1 by Sanofi: 6 open now, 9 under way, 1 of them phase 3. Of 57 finished, 13 (23%) have results posted.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 7th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2012, is one of 20 in phase 3, and was the 31st registered.
Sanofi’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 67 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objective:
The maximum study duration was up to approximately 54 weeks per participants:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).
Drug: HOE901-U300 (Insulin glargine new formulation)
Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Drug: Lantus (Insulin glargine)
Change In HbA1c From Baseline to Month 6 Endpoint
Time frame: Baseline, Month 6
Percentage of Participants With HbA1c <7% at Month 6 Endpoint
Time frame: Month 6
Percentage of Participants With HbA1c Less Than or Equal to 6.5% at Month 6 Endpoint
Time frame: Month 6
Change In Average Pre-Injection Self-Monitored Plasma Glucose (SMPG) From Baseline Month 6 Endpoint
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Average was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit.
Time frame: Baseline, Month 6
Change in Variability of Pre-injection SMPG From Baseline to Month 6 Endpoint
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit.
Time frame: Baseline, Month 6
Change in Fasting Plasma Glucose From Baseline to Month 6 Endpoint
Time frame: Baseline, Month 6
Percentage of Participants With Fasting Plasma Glucose (FPG) <5.6 mmol/L (100 mg/dL) At Month 6
Time frame: Month 6
Percentage of Participants With FPG <7.2 mmol/L (130 mg/dL) at Month 6 Endpoint
Time frame: Month 6
Change in 8--Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint
Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime.
Time frame: Baseline, Month 6
Change in Daily Average Total Insulin Dose From Baseline to Month 6 Endpoint
Time frame: Baseline, Month 6
Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint
DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction.
Time frame: Baseline, Month 6
Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12
Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).
Time frame: Up to Month 12
A total of 846 participants were screened, of whom 297 participants were screen failure and 549 participants were randomized.
| Milestone | HOE901--U300 | Lantus |
|---|---|---|
| Started | 274 | 275 |
| Modified intent-to-treat population | 273 | 273 |
| Completed | 219 | 225 |
| Not completed | 55 | 50 |
| Withdrew: Adverse event | 5 | 4 |
| Withdrew: Lack of efficacy | 5 | 2 |
| Withdrew: Protocol violation | 13 | 6 |
| Withdrew: Personal reason | 17 | 25 |
| Withdrew: Selection criterion / protocol violation | 7 | 5 |
| Withdrew: Lost to follow-up | 5 | 0 |
| Withdrew: Site closure / site withdrawal | 1 | 3 |
| Withdrew: Nonserious hypoglycemia | 0 | 3 |
| Withdrew: Perceived lack of efficacy | 1 | 1 |
| Withdrew: Possibly hypoglycemia | 1 | 0 |
| Withdrew: Serious adverse event of hypoglycemia | 0 | 1 |
| percentage of hemoglobin | HOE901--U300 | Lantus |
|---|---|---|
| Change In HbA1c From Baseline to Month 6 Endpoint | -0.40 ± 0.051 | -0.44 ± 0.051 |
| percentage of participants | HOE901--U300 | Lantus |
|---|---|---|
| Percentage of Participants With HbA1c <7% at Month 6 Endpoint | 16.8 | 15.0 |
| percentage of participants | HOE901--U300 | Lantus |
|---|---|---|
| Percentage of Participants With HbA1c Less Than or Equal to 6.5% at Month 6 Endpoint | 8.1 | 5.5 |
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Average was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit.
| millimole per liter (mmol/L) | HOE901--U300 | Lantus |
|---|---|---|
| Change In Average Pre-Injection Self-Monitored Plasma Glucose (SMPG) From Baseline Month 6 Endpoint | -1.16 ± 0.223 | -0.82 ± 0.233 |
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit.
| percentage of mean | HOE901--U300 | Lantus |
|---|---|---|
| Change in Variability of Pre-injection SMPG From Baseline to Month 6 Endpoint | -3.03 ± 1.573 | -1.76 ± 1.651 |
| mmol/L | HOE901--U300 | Lantus |
|---|---|---|
| Change in Fasting Plasma Glucose From Baseline to Month 6 Endpoint | -0.95 ± 0.263 | -1.14 ± 0.260 |
| percentage of participants | HOE901--U300 | Lantus |
|---|---|---|
| Percentage of Participants With Fasting Plasma Glucose (FPG) <5.6 mmol/L (100 mg/dL) At Month 6 | 9.9 | 12.8 |
| percentage of participants | HOE901--U300 | Lantus |
|---|---|---|
| Percentage of Participants With FPG <7.2 mmol/L (130 mg/dL) at Month 6 Endpoint | 25.3 | 25.6 |
Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime.
| mmol/L | HOE901--U300 | Lantus |
|---|---|---|
| 03:00 at Night (n= 156, 159) | -0.47 ± 4.56 | -0.67 ± 4.98 |
| Pre--Breakfast (n= 166, 167) | -0.86 ± 5.30 | -0.07 ± 5.20 |
| 2 Hours After Breakfast (n= 152, 156) | -0.62 ± 4.75 | -1.18 ± 5.66 |
| Pre--Lunch (n= 166, 166) | -0.95 ± 4.53 | -0.93 ± 4.76 |
| 2 Hours After Lunch (n= 163,163) | -0.13 ± 5.20 | -1.43 ± 5.37 |
| Pre--Dinner (n= 165,166) | -0.56 ± 6.00 | -1.74 ± 5.28 |
| 2 Hours After Dinner (n= 154,152) | -0.93 ± 5.27 | -1.19 ± 5.51 |
| Bedtime (n= 141,146) | -0.80 ± 5.39 | -1.91 ± 5.10 |
| U/kg | HOE901--U300 | Lantus |
|---|---|---|
| Change in Daily Average Total Insulin Dose From Baseline to Month 6 Endpoint | 0.19 ± 0.22 | 0.10 ± 0.16 |
DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction.
| units on a scale | HOE901--U300 | Lantus |
|---|---|---|
| Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint | 1.00 ± 0.331 | 1.41 ± 0.334 |
Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).
| percentage of participants | HOE901--U300 | Lantus |
|---|---|---|
| Any Hypoglycemia Event: All Hypoglycemia | 95.3 | 94.9 |
| Severe Hypoglycemia: All Hypoglycemia | 9.1 | 11.3 |
| Documented Symptomatic: All Hypoglycemia | 87.6 | 86.5 |
| Asymptomatic: All Hypoglycemia | 76.6 | 81.5 |
| Probable Symptomatic: All Hypoglycemia | 11.3 | 15.3 |
| Relative: All Hypoglycemia | 14.6 | 9.5 |
| Severe and/or Confirmed: All Hypoglycemia | 94.9 | 94.5 |
| Any Hypoglycemia Event: Nocturnal Hypoglycemia | 73.4 | 74.9 |
| Severe Hypoglycemia: Nocturnal Hypoglycemia | 3.3 | 3.3 |
| Documented Symptomatic: Nocturnal Hypoglycemia | 64.2 | 63.3 |
| Asymptomatic: Nocturnal Hypoglycemia | 35.0 | 38.9 |
| Probable Symptomatic: Nocturnal Hypoglycemia | 5.1 | 6.5 |
| Relative: Nocturnal Hypoglycemia | 4.0 | 5.5 |
| Severe and/or Confirmed: Nocturnal Hypoglycemia | 72.6 | 74.5 |
Collected over All Adverse Events (AE) were collected from signature of informed consent form up to study completion regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HOE901--U300 | — | 27/274 (9.9%) | 113/274 (41.2%) |
| Lantus | — | 26/275 (9.5%) | 86/275 (31.3%) |
| Event | HOE901--U300 | Lantus |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 16/274 | 13/275 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 2/274 | 1/275 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/274 | 2/275 |
| Atrioventricular block completeCardiac disorders | 1/274 | 0/275 |
| Coronary artery diseaseCardiac disorders | 1/274 | 0/275 |
| HypersensitivityImmune system disorders | 1/274 | 0/275 |
| CellulitisInfections and infestations | 1/274 | 0/275 |
| ErysipelasInfections and infestations | 1/274 | 0/275 |
| H1N1 influenzaInfections and infestations | 1/274 | 0/275 |
| PyelonephritisInfections and infestations | 1/274 | 0/275 |
| Event | HOE901--U300 | Lantus |
|---|---|---|
| NasopharyngitisInfections and infestations | 43/274 | 35/275 |
| Upper respiratory tract infectionInfections and infestations | 38/274 | 26/275 |
| HeadacheNervous system disorders | 17/274 | 13/275 |
| InfluenzaInfections and infestations | 16/274 | 14/275 |
| SinusitisInfections and infestations | 14/274 | 11/275 |
| Back painMusculoskeletal and connective tissue disorders | 14/274 | 7/275 |
Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment group and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment group to which they were randomized.
| Age, Continuous(years) | HOE901--U300 | Lantus | Total |
|---|---|---|---|
| Mean | 46.4 ± 13.9 | 48.2 ± 13.4 | 47.3 ± 13.7 |
| Sex: Female, Male(Participants) | HOE901--U300 | Lantus | Total |
|---|---|---|---|
| Female | 125 | 111 | 236 |
| Male | 149 | 164 | 313 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | HOE901--U300 | Lantus | Total |
|---|---|---|---|
| Mean | 27.6 ± 5.5 | 27.6 ± 4.7 | 27.6 ± 5.1 |
| Duration of Diabetes(years) | HOE901--U300 | Lantus | Total |
|---|---|---|---|
| Mean | 20.5 ± 12.7 | 21.4 ± 13.1 | 21.0 ± 12.9 |
| Glycated Hemoglobin (HbA1c)(participants) | HOE901--U300 | Lantus | Total |
|---|---|---|---|
| Less Than (<) 8% | 105 | 105 | 210 |
| Greater Than or Equal to (>=) 8% | 169 | 170 | 339 |
| Basal Insulin Daily Dose(units per kilogram (U/kg)) | HOE901--U300 | Lantus | Total |
|---|---|---|---|
| Mean | 0.381 ± 0.173 | 0.372 ± 0.152 | 0.376 ± 0.162 |
| Total Insulin Daily Dose(U/kg) | HOE901--U300 | Lantus | Total |
|---|---|---|---|
| Mean | 0.714 ± 0.278 | 0.724 ± 0.245 | 0.719 ± 0.262 |
Showing the first 100 of 147 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2012, a primary completion of Sep 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 7 months after primary completion. A results delay was requested in Nov 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine